Patents Assigned to Dainippon Sumitomo Pharma Co., Ltd. a corporation of Japan
  • Publication number: 20090192153
    Abstract: An adenine compound or its pharmaceutically acceptable salt as a medicament as shown following formula (1): wherein R1 is optionally substituted alkyl group, etc., X is oxygen atom, etc., A is 4 to 8 membered optionally substituted saturated or unsaturated heterocyclic group containing 1 to 2 hetero atoms selected from 1 to 3 nitrogen atoms, 0 to 1 oxygen atom and 0 to 1 sulfur atom, L1 and L2 are independently straight or branched chain alkylene, or a single bond, R2 is optionally substituted alkyl group, etc.
    Type: Application
    Filed: September 21, 2006
    Publication date: July 30, 2009
    Applicants: Dainippon Sumitomo Pharma Co., Ltd. a corporation of Japan, AstraZeneca Aktiebolag A corporation of Sweden
    Inventors: Kazuki Hashimoto, Tomoaki Nakamura, Kei Nakamura, Ayumu Kurimoto, Yoshiaki Isobe, Haruhisa Ogita, Ian Millichip, Thomas Mcinally, Roger Bonnert
  • Publication number: 20090105212
    Abstract: A novel adenine compound represented by the formula (1): wherein A represents an (un)substituted aromatic carbocycle or (un)substituted aromatic heterocycle; L1, L2, and L3 each independently represents linear or branched alkylene, etc.; R1 represents (un)substituted alkyl, (un)substituted aryl, etc.; R2 represents hydrogen or (un) substituted alkyl; R3 represents (un)substituted alkyl, etc., provided that R3 may be bonded to L2 or L3 to form a nitrogenous saturated heterocycle; and X represents oxygen, etc.; or a pharmaceutically acceptable salt of the compound. The compound and salt are useful as a medicine.
    Type: Application
    Filed: September 22, 2006
    Publication date: April 23, 2009
    Applicants: Dainippon Sumitomo Pharma Co., Ltd. a corporation of Japan, AstraZeneca Aktiebolag a corporation of Sweden
    Inventors: Yoshiaki Isobe, Ayumu Kurimoto, Kazuki Hashimoto, Tomoaki Nakamura, Kei Nakamura
  • Publication number: 20080269240
    Abstract: An adenine compound useful as a medicine represented by the following formula (1): [wherein R1 is halogen atom, optionally substituted alkyl group, optionally substituted aryl group, etc.; X is oxygen atom, sulfur atom, a single bond, etc.; A1 is optionally substituted and optionally saturated 4 to 8 membered heterocyclic group containing 1 to 2 hetero atoms selected from 1 to 3 nitrogen atoms, 0 to 1 oxygen atom, and 0 to 1 sulfur atom; A2 is optionally substituted 6 to 10 cyclic aromatic hydrocarbon group or optionally substituted 5 to 10 membered heterocyclic aromatic group; L1 and L2 are independently, substituted straight or branched alkylene or a single bond, etc.; L3 is optionally substituted straight or branched alkylene, etc.; R2 is hydrogen atom, optionally substituted alkyl group.] or its pharmaceutically acceptable salt.
    Type: Application
    Filed: September 21, 2006
    Publication date: October 30, 2008
    Applicants: Dainippon Sumitomo Pharma Co., Ltd. a corporation of Japan, AstraZeneca Aktiebolag A Corporation of Sweden
    Inventors: Kazuki Hashimoto, Tomoaki Nakamura, Kei Nakamura, Shingo Tojo, Ayumu Kurimoto, Yoshiaki Isobe, Hiroki Wada, Roger Bonnert